UA83041C2 - Композиция, которая включает ингибитор pde4 и ингибитор pde5 - Google Patents
Композиция, которая включает ингибитор pde4 и ингибитор pde5Info
- Publication number
- UA83041C2 UA83041C2 UAA200511710A UAA200511710A UA83041C2 UA 83041 C2 UA83041 C2 UA 83041C2 UA A200511710 A UAA200511710 A UA A200511710A UA A200511710 A UAA200511710 A UA A200511710A UA 83041 C2 UA83041 C2 UA 83041C2
- Authority
- UA
- Ukraine
- Prior art keywords
- inhibitor
- pde5
- pde4
- composition
- phosphodiesterase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Abstract
Изобретение касается комбинированного введения ингибитора PDE4 и ингибитора PDE5 для приготовления лекарственного средства, предназначенного для предотвращения или ослабления проявления симптомов заболевания, или лечения или уменьшения тяжести заболевания, которое выбирают из группы, которая включает хроническое обструктивное заболевание легких (ХОЗЛ), бронхиальную астму, аллергический бронхит, хронический бронхит, хроническую сердечную недостаточность, нефрит, ревматоидный артрит или эмфизему у пациента, который этого требует, в которой ингибитор PDE4 выбран из группы 3-циклопропилметокси-4-дифторметокси-N-(3,5-дихлорпирид-4-ил)-бензамид (рофлумиласт) или его фармацевтически приемлемой соли и ингибитор PDE5 выбран из группы, которая включает 5-[2-этокси-5-(4-метил-1-пиперазинилсульфонил)фенил]-1-метил-3-н-пропил-1,6-дигидро-7Н-пиразоло[4,3-d]пиримидин-7-он (силденафил), (6R, 12a)-2,3,6,7,12,12а-гексагидро-2-метил-6-(3,4-метилендиоксифенил)-пиразино[2',1':6,1]пиридо[3,4-b]индол-1,4-дион (тадалафил), 2-[2-этокси-5-(4-этилпиперазин-1-илсульфонил)фенил]-5-метил-7-пропилимидазо[5,1-f][1,2,4]триазин-4(ЗН)-он (варденафил) и фармацевтически приемлемые соли этих веществ.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03011609 | 2003-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA83041C2 true UA83041C2 (ru) | 2008-06-10 |
Family
ID=33462087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200511710A UA83041C2 (ru) | 2003-05-22 | 2004-05-19 | Композиция, которая включает ингибитор pde4 и ингибитор pde5 |
Country Status (23)
Country | Link |
---|---|
US (3) | US20060094723A1 (ru) |
EP (1) | EP1628682B1 (ru) |
JP (1) | JP2006528229A (ru) |
KR (1) | KR20060012004A (ru) |
CN (1) | CN1791429A (ru) |
AU (1) | AU2004241749B2 (ru) |
BR (1) | BRPI0410326A (ru) |
CA (1) | CA2525946C (ru) |
CO (1) | CO5660275A2 (ru) |
EA (1) | EA012279B1 (ru) |
EC (1) | ECSP056173A (ru) |
GE (1) | GEP20084342B (ru) |
IL (1) | IL171306A (ru) |
IS (1) | IS8181A (ru) |
MA (1) | MA27855A1 (ru) |
MX (1) | MXPA05012302A (ru) |
NO (1) | NO333501B1 (ru) |
NZ (1) | NZ544040A (ru) |
RS (1) | RS52730B (ru) |
TN (1) | TNSN05265A1 (ru) |
UA (1) | UA83041C2 (ru) |
WO (1) | WO2004103407A2 (ru) |
ZA (1) | ZA200508116B (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
EA009985B1 (ru) | 2003-03-10 | 2008-04-28 | Никомед Гмбх | Новый способ получения рофлумиласта |
JP2007504201A (ja) | 2003-09-05 | 2007-03-01 | アルタナ ファルマ アクチエンゲゼルシャフト | 真性糖尿病の治療のためのpde4阻害剤の使用 |
JP2007536350A (ja) * | 2004-05-10 | 2007-12-13 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肺気腫の予防又は治療のためのロフルミラストの使用 |
WO2006094942A1 (en) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
US8017633B2 (en) | 2005-03-08 | 2011-09-13 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
CA2601250C (en) | 2005-03-16 | 2014-10-28 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
DE102005016345A1 (de) * | 2005-04-09 | 2006-10-12 | Bayer Healthcare Ag | Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
ES2433661T3 (es) | 2005-04-19 | 2013-12-12 | Takeda Gmbh | Roflumilast para el tratamiento de hipertensión pulmonar |
NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
EA032476B1 (ru) | 2006-07-05 | 2019-06-28 | Астразенека Аб | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ |
AU2007303846B2 (en) * | 2006-10-04 | 2011-03-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists |
WO2010013925A2 (en) * | 2008-07-31 | 2010-02-04 | Dong-A Pharmaceutical. Co., Ltd. | Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof |
JP2014526461A (ja) * | 2011-09-09 | 2014-10-06 | エスケー ケミカルズ カンパニー,リミテッド | Pde5抑制剤を含む皮膚しわ改善用組成物 |
EA201791271A1 (ru) * | 2012-05-31 | 2018-01-31 | Фенекс Фармасьютикалз Аг | ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ |
EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
EP3165224A1 (en) | 2015-11-09 | 2017-05-10 | Albert-Ludwigs-Universität Freiburg | Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders |
US10058545B2 (en) * | 2016-08-09 | 2018-08-28 | Cipla Limited | Method of treating pulmonary arterial hypertension |
CN107648224A (zh) * | 2017-10-31 | 2018-02-02 | 泰州中国医药城中医药研究院 | 一种治疗和预防心力衰竭药物及其在制药中的应用 |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
CN108976107B (zh) * | 2018-08-23 | 2021-03-23 | 南方医科大学 | 3-芳基-4-烷氧基苄胺衍生物及其制备方法和应用 |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US20230124467A1 (en) * | 2020-03-03 | 2023-04-20 | Mios Pharmaceuticals Limited | Compounds and methods for treating diseases and/or conditions caused by coronavirus |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
CZ290266B6 (cs) | 1993-07-02 | 2002-06-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
US5817670A (en) * | 1994-08-29 | 1998-10-06 | Yamanouchi Pharmaceutical Co., Ltd. | Naphthyridine derivatives and pharmaceutical compositions thereof |
US6127363A (en) * | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
SK287161B6 (sk) | 1997-11-12 | 2010-02-08 | Bayer Healthcare Ag | 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie |
US6417190B1 (en) * | 1998-12-17 | 2002-07-09 | Boehringer Ingelheim Pharma Kg | Tricyclic nitrogen heterocycles as PDE IV inhibitors |
TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
EA200300836A1 (ru) * | 2001-02-15 | 2004-02-26 | Алтана Фарма Аг | Производные фталазинон-пиперидина в качестве ингибиторов pde4 |
ATE347361T1 (de) * | 2001-05-25 | 2006-12-15 | Boehringer Ingelheim Pharma | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
GB0202254D0 (en) * | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
-
2004
- 2004-05-19 WO PCT/EP2004/050869 patent/WO2004103407A2/en active Application Filing
- 2004-05-19 GE GEAP20049115A patent/GEP20084342B/en unknown
- 2004-05-19 BR BRPI0410326-2A patent/BRPI0410326A/pt active Search and Examination
- 2004-05-19 CN CNA2004800133493A patent/CN1791429A/zh active Pending
- 2004-05-19 MX MXPA05012302A patent/MXPA05012302A/es active IP Right Grant
- 2004-05-19 NZ NZ544040A patent/NZ544040A/en not_active IP Right Cessation
- 2004-05-19 EA EA200501690A patent/EA012279B1/ru not_active IP Right Cessation
- 2004-05-19 EP EP04766017.0A patent/EP1628682B1/en active Active
- 2004-05-19 KR KR1020057021796A patent/KR20060012004A/ko active Search and Examination
- 2004-05-19 RS YU20050858A patent/RS52730B/sr unknown
- 2004-05-19 AU AU2004241749A patent/AU2004241749B2/en not_active Ceased
- 2004-05-19 US US10/556,888 patent/US20060094723A1/en not_active Abandoned
- 2004-05-19 JP JP2006530210A patent/JP2006528229A/ja active Pending
- 2004-05-19 UA UAA200511710A patent/UA83041C2/ru unknown
- 2004-05-19 CA CA2525946A patent/CA2525946C/en not_active Expired - Fee Related
-
2005
- 2005-10-07 ZA ZA200508116A patent/ZA200508116B/en unknown
- 2005-10-09 IL IL171306A patent/IL171306A/en not_active IP Right Cessation
- 2005-10-18 TN TNP2005000265A patent/TNSN05265A1/en unknown
- 2005-11-17 EC EC2005006173A patent/ECSP056173A/es unknown
- 2005-12-12 MA MA28653A patent/MA27855A1/fr unknown
- 2005-12-14 NO NO20055941A patent/NO333501B1/no not_active IP Right Cessation
- 2005-12-14 IS IS8181A patent/IS8181A/is unknown
- 2005-12-16 CO CO05126935A patent/CO5660275A2/es active IP Right Grant
-
2010
- 2010-05-24 US US12/785,973 patent/US20100234382A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,675 patent/US20120196867A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL171306A (en) | 2013-08-29 |
MA27855A1 (fr) | 2006-04-03 |
AU2004241749B2 (en) | 2010-03-25 |
US20120196867A1 (en) | 2012-08-02 |
NO333501B1 (no) | 2013-06-24 |
BRPI0410326A (pt) | 2006-05-23 |
ECSP056173A (es) | 2006-04-19 |
NZ544040A (en) | 2009-03-31 |
CA2525946A1 (en) | 2004-12-02 |
NO20055941L (no) | 2005-12-14 |
ZA200508116B (en) | 2007-01-31 |
EP1628682A2 (en) | 2006-03-01 |
MXPA05012302A (es) | 2006-01-30 |
RS52730B (sr) | 2013-08-30 |
EA200501690A1 (ru) | 2006-06-30 |
US20060094723A1 (en) | 2006-05-04 |
KR20060012004A (ko) | 2006-02-06 |
RS20050858A (en) | 2007-12-31 |
IS8181A (is) | 2005-12-14 |
GEP20084342B (en) | 2008-03-25 |
WO2004103407A2 (en) | 2004-12-02 |
CN1791429A (zh) | 2006-06-21 |
TNSN05265A1 (en) | 2007-07-10 |
EA012279B1 (ru) | 2009-08-28 |
CA2525946C (en) | 2013-01-29 |
JP2006528229A (ja) | 2006-12-14 |
US20100234382A1 (en) | 2010-09-16 |
CO5660275A2 (es) | 2006-07-31 |
AU2004241749A1 (en) | 2004-12-02 |
EP1628682B1 (en) | 2013-09-25 |
WO2004103407A3 (en) | 2005-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN05265A1 (en) | Composition comprising a pde4 inhibitor and a pde5 inhibitor | |
MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
ES2195785A1 (es) | Nuevos derivados de piridazin-3(2h)-ona. | |
NO2007010I1 (no) | Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt | |
EP1554256A4 (en) | INHIBITORS OF PIPERIDINO PYRIMIDINE DIPEPTIDYL PEPTIDASE USEFUL IN THE TREATMENT OF DIABETES | |
EP1385508A4 (en) | DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
IS7817A (is) | Fenýlalanín afleiður sem dípeptidýl peptíðasa hindrar til að meðhöndla eða fyrirbyggja sykursýki. | |
EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
WO2004062625A3 (en) | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease | |
WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
WO2004112701A3 (en) | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
EP1624874A4 (en) | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IN THE TREATMENT OR PREVENTION OF DIABETES | |
GB0223040D0 (en) | Therapeutic compounds | |
WO2005018545A3 (en) | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
MXPA04000793A (es) | Novedoso metodo terapeutico. | |
HRP20050572A2 (en) | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | |
ATE547104T1 (de) | Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen | |
HRP20030609A2 (en) | Use of il-18 inhibitors for the treatment and/or prevention of heart disease | |
HUP0500078A2 (hu) | PDE inhibitort és leukotrién antagonistát tartalmazó kombinált gyógyszerkészítmény | |
HUP0301451A3 (en) | Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies |